Compare DexCom, Inc. (DXCM) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NRG Energy Inc — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while NRG Energy Inc trades at $135.34 (market cap $29.10B). The key difference: DexCom, Inc. and NRG Energy Inc are close in size by market cap, and NRG Energy Inc pays a 1.38% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NRG | |
|---|---|---|
Market Cap | $28.06B | $29.10B |
Sector | Health | Utilities |
52-Week High | $89.53 | $184.03 |
52-Week Low | $54.84 | $120.65 |
Enterprise Value | $27.03B | $52.92B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
NRG Energy trades at $138.36, down 0.8% on the day, with a bearish technical signal and key support at $136. Fundamentally, the company reported 2025 revenue of $30.71 billion and net income of $864 million, though net margin is thin at 0.74%. Recent earnings show mixed results, with a Q1 2026 miss, while analysts maintain a consensus buy rating with a $190 price target. Cash flow trends are volatile, with 2025 net cash flow positive at $3.83 billion but 2026 projected negative.
The stock presents a valuation case with a high P/E of 151.54 offset by a reasonable P/S of 0.85. Upside is supported by analyst optimism and exposure to energy demand trends, but risks include volatile cash flows, high debt levels, and execution challenges in a competitive market. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
